Switching From Oral Dopamine Agonists to Rotigotine

PHASE4CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

December 31, 2015

Conditions
Restless Legs SyndromeEkbom SyndromeWillis-Ekbom Disease
Interventions
DRUG

Rotigotine

Rotigotine is FDA approved for the treatment of Restless Legs Syndrome at doses of 1 mg/24h, 2 mg/24h, and 3 mg/24h. The prescribed dose of rotigotine may be achieved using single or multiple patches. Subjects will titrate the dose based on discussions with the investigator.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

UCB Pharma

INDUSTRY

lead

John Winkelman, MD, PhD

OTHER